Drug Trial Radar · NCT02627963
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
Last checked: Nov 19, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
May 24, 2016
Primary completion
Oct 4, 2018
Study completion Jun 21, 2021
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC). Participants will be randomized (1:1) to treatment with tivozanib or sorafenib. Participants will be stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk category (favorable; intermediate; poor) and prior therapy (two prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI); a prior checkpoint inhibitor \[programmed cell death -1 protein (PD-1) or PD-1 ligand (PD1-L) inhibitor\] plus a prior VEGFR TKI; a prior VEGFR TKI plus any other systemic agent). All participants will be evaluated for progression free survival, overall survival, objective response rate, and the duration of response as well as safety and tolerability. Pharmacokinetic (PK) analyses are also included in study.
Conditions
- Carcinoma, Renal Cell
Interventions
Tivozanib hydrochlorideDrug
Tivozanib hydrochloride
SorafenibDrug
Sorafenib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks (up to approximately 5 years)
Locations
191 sites in 12 countries. Site status is shown where the registry gives one.
University Of UA Cancer Center(UACC)/DH-SJHMC
Phoenix, Arizona
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona
Arizona Oncology - Phoenix - Deer Valley Women's Center Loca
Phoenix, Arizona
Arizona Oncology - Scottsdale
Scottsdale, Arizona
City of Hope Comprehensive Breast Cancer Center
Duarte, California
Long Beach Memorial Medical Center
Fountain Valley, California
Marin Cancer Care
Greenbrae, California
UCLA
Los Angeles, California
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Loyola University Medical Center
Maywood, Illinois
Investigative Clinical Research of Indiana
Indianapolis, Indiana
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
Nebraska Methodist Hospital
Omaha, Nebraska
Midwest Cancer Center
Omaha, Nebraska
Urology Cancer Center, PC
Omaha, Nebraska
Comprehensive Cancer Center Of Nevada
Henderson, Nevada
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
Comprehensive Cancer Center Of Nevada
Las Vegas, Nevada
Comprehensive Cancer Center of Nevada
Las Vegas, Nevada
Hackensack University Medical Center - John Theurer Cancer
Hackensack, New Jersey
New York Oncology Hematology, P.C.
Albany, New York
New York Oncology Hematology, PC
Albany, New York
New York Oncology Hematology, P.C.
Clifton Park, New York
New York Presbyterian Hospital
New York, New York
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York
University of Rochester Medical Center
Rochester, New York
Montefiore Medical Center
The Bronx, New York
Wake Forest University Baptist Medical Center (WFUBMC)
Winston-Salem, North Carolina
Cleveland Clinic
Cleveland, Ohio
Ohio Cancer Specialists
Mansfield, Ohio
North Coast Cancer Care, Inc
Sandusky, Ohio
Wooster Specialty and Surgery Center
Wooster, Ohio
St. Luke University Health Network
Easton, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania
Texas Oncology - Austin Midtown
Austin, Texas
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.